Abstract：【Objective】To investigate the clinical efficacy and quality of life of patients with advanced non small cell lung cancer (NSCLC) treated with Cinobufacini tablets and Erbitux injection combined TP chemotherapy.【Methods】Seventy-three cases of patients with advanced NSCLC were divided into the observation group (group A) and the control group (group B) . The group B was treated with TP (paclitaxel and cisplatin) chemotherapy, and the group A was treated with cinobufacini tablets and Erbitux injection on the basis of treatment in the group B. The short-term efficacy, adverse reactions, and related changes before and after treatment were compared between the two groups.【Results】The total effective rate of the observation group was 59.46% (22/37) , which was significantly higher than 33.33% (12/36) of the control group (P<0.05) , but there was no significant difference in the disease control rate between the two groups (P>0.05) ; the levels of serum interleukin -6 (IL-6) , IL-10, CA125, carcinoembryonic antigen (CEA) and vascular endothelial growth factor (VEGF) in the observation group were significantly lower than those in the observation group after treatment; IL-17, TNF-αlevel was significantly higher than that of the control group, and the difference was significant (P<0.05) ; the improvement rate of survival quality in the observation group was 48.65% (18/37) , which was significantly higher than 25% (9/36) in the control group (P < 0.05) ; the incidence of nausea and vomiting, white blood cell reduction and anemia in the observation group were lower than those in the control group (P<0.05) .【Conclusion】Cinobufacini tablets, Erbitux injection combined with TP chemotherapy can effectively improve the short-term efficacy, regulate immune abnormalities, enhance immune function, and significantly improve the quality of life in patients with advanced NSCLC.
2017, Vol. 34 
